Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Research & Development (2016 - 2025)

Iradimed (IRMD) has disclosed Research & Development for 13 consecutive years, with $799031.0 as the latest value for Q4 2025.

  • Quarterly Research & Development rose 40.08% to $799031.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, up 5.05% year-over-year, with the annual reading at $3.0 million for FY2025, 5.05% up from the prior year.
  • Research & Development for Q4 2025 was $799031.0 at Iradimed, up from $674362.0 in the prior quarter.
  • The five-year high for Research & Development was $3.0 million in Q1 2023, with the low at $452555.0 in Q3 2023.
  • Average Research & Development over 5 years is $752752.1, with a median of $631856.0 recorded in 2024.
  • The sharpest move saw Research & Development surged 477.92% in 2023, then crashed 72.63% in 2024.
  • Over 5 years, Research & Development stood at $494851.0 in 2021, then rose by 22.21% to $604744.0 in 2022, then increased by 7.56% to $650435.0 in 2023, then dropped by 12.3% to $570404.0 in 2024, then surged by 40.08% to $799031.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $799031.0, $674362.0, and $877362.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.